- Home
- / Ovid Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Ovid Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.2
2024-10-29
Market Capitalization
$84.5 M
2024-10-29
Revenue
$7.3 M
FY, 2025
CreditSafe Score
?
Score changed on Jul 19, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.6M | 208.4M | 1.5M | 391.7K | 566.0K | 7.3M | |||
| General and administrative expense | 15.0M | 19.1M | 19.3M | 30.6M | 37.2M | 32.4M | 31.1M | 25.7M | 24.1M |
| Operating expense total | 65.0M | 52.9M | 61.4M | 94.4M | 57.1M | 62.5M | 49.7M | ||
| EBIT | (65.0M) | (52.9M) | (61.4M) | (81.4M) | (55.5M) | (59.3M) | (61.9M) | (42.4M) | |
| EBIT margin, % | -645.4% | -3696.4% | -10933.7% | -585.2% | |||||
| Interest income | 3.9M | ||||||||
| Pre tax profit | 124.2M | (54.2M) | (52.3M) | (26.4M) | (17.4M) | ||||
| Income tax expense | 1.3M | ||||||||
| Net Income | (64.8M) | (52.0M) | (60.5M) | (81.0M) | 122.8M | (54.2M) | (52.3M) | (26.4M) | |
| EPS | (0.8) |